Abstract
BackgroundGlucose transporter-1 (GLUT-1) exhibits altered expression in colorectal cancer (CRC). The aim of this study was to explore the association between GLUT-1 and survival conditions, as well as clinical features in CRC by meta-analysis.Materials and MethodsRelevant studies were searched through predefined strategies, hazard ratios (HRs), odds ratios (ORs), and their 95% confidence intervals (CIs) were used as effective measures.ResultsA total of 14 studies with 2,077 patients were included in this meta-analysis. The results showed that GLUT-1 was not significantly associated with overall survival (OS) (HR=1.28, 95% CI=0.86–1.91, p=0.22) or disease-free survival (DFS) (HR=1.71, 95% CI=0.78–3.72, p=0.179). However, subgroup analysis indicated that GLUT-1 was a significant biomarker for poor DFS in rectal cancer (HR=2.47, 95% CI=1.21–5.05, p=0.013). GLUT-1 expression was also found to be significantly correlated with the presence of lymph node metastasis (n=8, OR=2.14, 95% CI=1.66–2.75, p<0.001), T stage (n=6, OR=1.73, 95% CI=1.17–2.58, p=0.007), higher Dukes stage (n=5, OR=2.92, 95% CI=2.16–3.95, p<0.001), female sex (n=4, OR=2.92, 95% CI=2.16–3.95, p<0.001), and presence of liver metastasis (n=3, OR=1.82, 95% CI=1.06–3.12, p=0.03).ConclusionIn conclusion, this meta-analysis showed that GLUT-1 was associated with poor DFS in rectal cancer (RC). Furthermore, GLUT-1 was also an indicator of aggressive clinical features in CRC.
Highlights
Colorectal cancer (CRC) is the third most prevalent cancer and the second leading cause of cancer-related death worldwide [1]
The results showed that Glucose transporter-1 (GLUT-1) was not significantly associated with overall survival (OS) (HR=1.28, 95% confidence intervals (CIs)=0.86–1.91, p=0.22) or disease-free survival (DFS) (HR=1.71, 95% CI=0.78–3.72, p=0.179)
GLUT-1 expression was found to be significantly correlated with the presence of lymph node metastasis (n=8, odds ratios (ORs)=2.14, 95% CI=1.66– 2.75, p
Summary
Colorectal cancer (CRC) is the third most prevalent cancer and the second leading cause of cancer-related death worldwide [1]. Significant advances have been achieved in the treatment of CRC, the 5-year survival rate is 64% [3, 4]. Confounding this is that fact that about one-fifth of CRC patients are in metastatic disease at first diagnosis. We collected all relevant studies and performed a quantitative meta-analysis to investigate the prognostic and clinical role of GLUT-1 in CRC. To our knowledge, this metaanalysis is the first one on this subject to date. Glucose transporter-1 (GLUT-1) exhibits altered expression in colorectal cancer (CRC). The aim of this study was to explore the association between GLUT-1 and survival conditions, as well as clinical features in CRC by meta-analysis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
